<DOC>
	<DOCNO>NCT00771979</DOCNO>
	<brief_summary>The aim study compare different formulation AZD0530 absorb body . As clinical trial , safety tolerability drug evaluate .</brief_summary>
	<brief_title>Relative Bioavailability Phase II Phase III Formulations AZD0530</brief_title>
	<detailed_description />
	<mesh_term>Saracatinib</mesh_term>
	<criteria>Female subject must Non childbearing potential Body mass index 19 30 kg/m2 weigh 50100 kg Presence clinically significant illness Abnormal vital sign History condition may put subject risk participate study Participation another clinical study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Healthy Volunteers</keyword>
	<keyword>Relative Bioavailability</keyword>
</DOC>